T1	Participants 434 460	diazoxide-treated patients
T2	Participants 766 774	patients
T3	Participants 823 831	patients
T4	Participants 902 910	patients
T5	Participants 1232 1240	patients
T6	Participants 1285 1293	patients
T7	Participants 137 223	in 13 patients and the alpha-beta adrenoceptor blocking agent labetalol in 12 patients
